Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S15a pseudogene 12 (RPS15AP12) is a processed pseudogene transcribed as a long noncoding RNA that does not encode a functional protein but exerts regulatory effects in cancer. It acts as a molecular “sponge” for miR-96-3p, preventing this microRNA from repressing RPS15A, thus promoting RPS15A expression. RPS15AP12 enhances the growth, migration, and metastatic capacity of ovarian cancer cells and suppresses innate immune signaling through inhibition of RIG-I/MDA5 and downstream interferon pathways. RPS15AP12 is not a traditional therapeutic target as it is a noncoding pseudogene, but it may play a functional role in cancer progression and could potentially be considered for future biomarker or RNA-based therapeutic strategies.
Acts as a competitive endogenous RNA (ceRNA) sequestering miR-96-3p, thereby promoting the expression of its parent gene, RPS15A.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S15a pseudogene 12 (RPS15AP12).